Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer (NASDAQ: SEER) has announced a non-exclusive commercial agreement with Thermo Fisher Scientific, enabling the integration of Thermo Fisher’s Orbitrap mass spectrometry systems with Seer’s Proteograph Product Suite. This collaboration aims to enhance end-to-end proteomics workflows, helping researchers achieve unbiased, deep proteome analysis. With both companies committed to advancing proteomics in emerging fields like proteogenomics, the combined solution will be readily available, reflecting a significant step toward expanding proteomics accessibility in various scientific markets.
Seer, a life sciences company, announced a non-exclusive agreement with Bruker Corporation to market the timsTOF Pro mass spectrometer alongside its Proteograph Product Suite. This collaboration aims to create an integrated proteomics solution that enhances accessibility for researchers. The Proteograph enables deep and rapid analysis of thousands of proteins, making it suitable for large-scale studies. Leaders from both companies emphasize the partnership’s potential to accelerate the adoption of unbiased proteomics workflows across various applications.
Seer, Inc. (Nasdaq: SEER), a life sciences company, will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:40 a.m. PT. The event will feature a presentation and Q&A session with company management. A live webcast will be accessible through the Investor section of Seer's website, with an archived replay available post-conference.
Seer focuses on delivering unbiased, rapid, and scalable proteomics information, primarily through its Proteograph™, enhancing scientific research efficiency.
Seer, a life sciences company, successfully closed its initial public offering (IPO) with 10,592,106 shares of Class A common stock priced at $19.00 per share, raising approximately $201.3 million. The IPO includes the full exercise of underwriters' options for an additional 1,381,579 shares. Seer's stock began trading on the Nasdaq under the ticker symbol SEER on December 4, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley.